Overview of Dolex-P

What is Dolex-P? Quick Facts

Property	Description
Active ingredient	Paracetamol (Acetaminophen) & Tramadol Hydrochloride
Form	Oral solid formulation (Tablet)
Pharmacological class	Multimodal Analgesic, Central Nervous System Agent
Common use	Pain signal attenuation and relief from discomfort
Origin	Synthetic

The medicinal entity Dolex-P is a fixed-dose combination (FDC) pharmaceutical preparation that delivers two distinct pharmacological agents within a single oral solid formulation. It is a synthetic compound classified as a Multimodal Analgesic, designed to provide comprehensive pain management through a combined mechanism of action.

Identity and Pharmacological Class

Dolex-P is primarily identified by its dual composition, representing a fixed-dose combination (FDC) product that unites a non-opioid analgesic and a synthetic opioid analgesic. This strategic pairing results in its classification as a Multimodal Analgesic, an approach recognized for its efficacy in addressing discomfort. Unlike single-component analgesics, the FDC format of Dolex-P provides a precise, established ratio of its ingredients, a distinctive feature ensuring consistency in its dual therapeutic contribution.

Composition: The Paracetamol and Tramadol Combination

The two active ingredients are Paracetamol (Acetaminophen) and Tramadol Hydrochloride. Paracetamol contributes by reducing the central nervous system's response to pain stimuli, while Tramadol acts as a centrally-acting analgesic, affecting the brain's opioid receptors. The oral solid formulation ensures the simultaneous delivery of both agents for maximum synergistic action. The fixed ratio of these two agents is engineered to deliver a combined effect greater than the individual components could provide alone.

General Purpose of this Fixed-Dose Combination

The overarching general purpose of the Dolex-P combination is to achieve significant pain signal attenuation and effective pain management. By combining a non-opioid and a synthetic opioid in an FDC, the medicine utilizes different biological pathways to disrupt the pain process. This strategy of Multimodal Analgesia provides an established method for enhancing relief and improving the scope of general discomfort management, frequently employed for managing acute flare-ups.

What side effects are possible with Dolex-P?

Possible side effects and safety information

The safety profile of the Paracetamol/ Tramadol fixed-dose combination reflects the established risks of both active components, as documented in official government regulatory sources.

Officially Classified Adverse Reactions

The most frequently documented effects are categorized by frequency and System- Organ Class ( SOC).

Frequency Classification	Gastrointestinal Disorders	Nervous System Disorders
Very Common (ge 1/10)	Nausea	Dizziness, Somnolence (drowsiness)
Common (ge 1/100 to < 1/10)	Vomiting, Constipation, Dry Mouth	Headache, Confusional State

Other common effects include increased sweating ( hyperhidrosis), anxiety, and insomnia. Rarer documented effects include drug dependence and anaphylaxis.

Serious Adverse Reactions and Regulatory Constraints

Official labeling highlights severe risks, particularly linked to the Tramadol component, including Seizures ( Convulsions) and Respiratory Depression. The Paracetamol component introduces the risk of Hepatotoxicity ( Liver Failure), which is the basis for the maximum daily dose limitation.

The medication is contraindicated in patients with severe hepatic impairment and in cases of acute intoxication with CNS depressants. Use is also contraindicated in severe renal impairment.

Population and Exposure Safety Patterns

Dizziness, Somnolence, and Nausea are frequently observed early in the course of treatment. Regulatory data indicates that the risk of physical dependence increases with long- term exposure. Older patients ( over age 75) may exhibit increased sensitivity, necessitating careful consideration of their profile.

Overdose and Emergency Response

An overdose of the Paracetamol and Tramadol fixed-dose combination requires immediate medical intervention due to the potential for severe, life-threatening toxicity from both components. Regulatory labeling mandates that immediate medical attention and contact with emergency services must be secured, even if the individual appears well, as the most serious complications can have a delayed onset.

Documented Manifestations and Severe Outcomes

The official overdose profile is defined by dual toxicity. Overdose of the paracetamol component may initially present with non-specific signs such as nausea, vomiting, and pallor, but the critical risk is dose-dependent hepatic necrosis and progression to fatal hepatic failure. The tramadol component's toxicity is characterized by central nervous system (CNS) depression, including somnolence, miosis, and seizures. Severe outcomes documented in regulatory sources include respiratory depression leading to respiratory paralysis, circulatory collapse, and cardiac arrest.

Emergency Management and Monitoring

Management is defined as symptomatic and supportive treatment. The label documents component-specific antidotes: N-acetylcysteine for paracetamol toxicity and Naloxone to partially reverse tramadol-induced respiratory effects. Hospital monitoring is required, including the continuous monitoring of vital signs and laboratory assessments for potential liver function abnormalities. Patients with pre-existing hepatic impairment or chronic alcoholism are noted to have an increased risk of toxicity.

Therapeutic Uses of Dolex-P

What Dolex-P Treats: Main Uses and Benefits

The primary therapeutic role of Dolex-P (the Paracetamol and Tramadol fixed-dose combination) is to provide symptomatic relief for acute pain that is difficult to manage with non-opioid medications alone. It is applied across domains where short-term, supportive symptom management is appropriate.

This combination is commonly used when the acute pain experienced by patients is severe, and for which alternative treatments may be inadequate. This medication is commonly used to help with pronounced symptoms in conditions where symptoms may intensify temporarily, such as pain following surgical interventions, acute musculoskeletal pain, or flare-ups of chronic conditions like osteoarthritis.

“The combined approach offers symptomatic relief that helps patients cope more steadily with difficult episodes.”

Management of Moderate to Severe Acute Pain Episodes

This medication is used to address pronounced symptoms when pain intensity has escalated to a moderate or severe level. It is relevant in clinical settings marked by heightened patient distress, such as following sudden injuries, dental procedures, or surgical interventions. This management approach provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Support for Challenging Musculoskeletal Pain Flare-Ups

Dolex-P is applicable in conditions marked by episodic or fluctuating symptom patterns, particularly intense musculoskeletal pain. It is commonly used when symptoms cluster into patterns requiring additional symptomatic support. For the patient, this offers symptomatic relief that helps them cope more steadily with difficult episodes and assists with maintaining functional stability.

Quick Fact: Relief for Moderate to Severe Acute Pain

Regulatory References

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN tablet - DailyMed - NIH

Eligibility and Restrictions for Use

Dolex-P is a combination medicine, typically containing a non-steroidal anti-inflammatory drug (NSAID) and Paracetamol (Acetaminophen), and its suitability depends on an individual's medical history.

Who Can Use Dolex-P (With Caution and Medical Advice)

Most healthy adults suffering from short-term pain, inflammation, and fever may be candidates for this medication. However, use requires a thorough consultation with a healthcare professional, especially for:

Patients with mild to moderate kidney or liver disease.
Individuals with a history of gastrointestinal problems or bleeding risks.
Elderly patients, who may require a lower, adjusted dose.

Who Should NOT Use Dolex-P

Due to the components of Dolex-P, it is generally contraindicated for certain patient populations to minimize the risk of serious adverse effects. Patients should avoid this medication if they have:

A known allergy or severe hypersensitivity reaction to any component of the drug or to other NSAIDs (e.g., aspirin).
Severe, active, or recurrent stomach ulcers or gastrointestinal bleeding.
Severe liver disease or active liver failure.
Severe kidney disease or end-stage renal failure.
Severe heart failure, recent myocardial infarction, or those undergoing coronary artery bypass graft (CABG) surgery.
The drug is generally not recommended for use in pregnant women, especially during the last trimester, or in breastfeeding mothers unless specifically advised by a physician who has weighed the benefits against the risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Interacting Categories

Medicinal product categories with documented interactions include MAO Inhibitors, other CNS Depressants (including alcohol), Serotonergic Drugs, CYP2D6 Inhibitors, CYP3A4 Inhibitors, CYP3A4 Inducers, and Warfarin derivatives. Specific substances, such as Carbamazepine and other Tramadol- or Paracetamol-containing products, are explicitly addressed in regulatory documents.

Officially Described Interaction Effects

Regulatory documents state that co-administration with CYP2D6 Inhibitors (e.g., Fluoxetine) may decrease the level of the active M1 metabolite, potentially reducing the analgesic effect. CYP3A4 Inducers (e.g., Carbamazepine, St. John's Wort) increase Tramadol metabolism, which can lead to decreased drug exposure. Pharmacodynamic interactions primarily involve additive effects, resulting in enhanced CNS depression or an increased risk of Serotonin Syndrome and seizures when combined with serotonergic agents.

Regulatory Restrictions and Timing Rules

Use of this product is contraindicated concurrently or within 14 days of discontinuing MAO Inhibitor therapy. It is also contraindicated to co-administer Dolex-P with other Tramadol- or Paracetamol-containing products. Co-administration with the CYP3A4 inducer Carbamazepine is not recommended. For patients with Severe Renal Impairment, regulatory labels mandate that the maximum dose must be restricted and the dosing interval must be prolonged.

Connection to the Overall Interaction Profile

The official interaction profile defines both pharmacodynamic augmentation (e.g., with CNS depressants) and pharmacokinetic modification (via CYP enzymes) as the primary risks. This framework establishes the specific combinations that are contraindicated or not recommended, alongside mandatory timing rules and necessary population-dependent adjustments found within the regulatory documents.

Mechanism of Action

How Dolex-P Works

Dolex-P exerts its action across multiple pharmacological domains, engaging distinct mechanistic pathways to influence overactive or dysregulated physiological processes.

Central Inhibition of Pain Signaling

This domain involves the drug's effect on enzyme-mediated pathways within the central nervous system (CNS), primarily through its analgesic component. The drug modulates cyclooxygenase (COX) pathways, particularly in the brain and spinal cord, reducing the synthesis of prostaglandins. This modification of early molecular steps in the signaling cascade leads to modulation of signal transduction within targeted neuronal pathways.

Adrenergic Receptor Modulation

This domain is utilized when the formulation includes a component that acts as an agonist on alpha-1 adrenergic receptors. This effect initiates a signaling sequence that leads to the constriction of blood vessels (vasoconstriction) in targeted peripheral systems, such as the nasal mucosa. This engagement of mechanisms results in altered hydrostatic pressure and reduced luminal diameter within the targeted peripheral vessels.

Dosage and Administration Information

Dolex-P, a fixed-dose combination of Tramadol and Paracetamol, is administered orally as a solid tablet formulation. The initial dose for adults is two tablets, containing a combined 75 mg of Tramadol and 650 mg of Paracetamol. Subsequent doses are managed on an as-needed basis for relief, but a strict time constraint must be observed.

Dosing frequency is managed by an interval of no less than 4 to 6 hours between doses. There is an absolute maximum limit of 8 tablets per day, corresponding to 300 mg of Tramadol and 2600 mg of Paracetamol, to control overall consumption. The duration of use is generally restricted to the short-term, with use for not more than five days.

For proper administration, the tablets must be swallowed whole using liquid and are not intended to be crushed or broken. The ingestion schedule allows for flexibility, as the medicine may be taken with or without food. Use is subject to procedural restrictions: the drug must not be co-administered with any other medication containing its active ingredients. Furthermore, specific dose adjustments are established for certain patient populations, such as limiting the maximum dose to two tablets every 12 hours for individuals with severe renal impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dolex-P

Evidence for Use in Moderate to Severe Acute Pain

This area of research has primarily relied on short-term, single-dose, and multiple-dose controlled trials (Randomized Controlled Trials or RCTs) and subsequent systematic reviews. These studies were applied in research contexts involving episodic symptom patterns, focusing on the measurements of symptoms over defined time intervals, often after events like dental surgery or minor orthopedic procedures. Comparisons research examined were typically made against a non-medicated placebo or against the individual components—Paracetamol alone or Tramadol alone. The studies monitored outcomes related to patient-reported perceived discomfort, examining intensity and functional measures. Findings describe patterns observed in the studies related to the measured changes in symptom intensity and the time until a pre-defined symptom intensity level was reached or passed.

Evidence for Use in Chronic Non-Cancer Pain

The combination was studied in populations with conditions marked by functional limitations, such as chronic low back pain and osteoarthritis. Research explored the outcomes of this combination versus placebo or other long-term options. The study outcomes examined extended beyond simple pain intensity, including outcomes reflecting daily functioning or activity level, as assessed through patient-reported scales over defined time intervals. Intermediate-term trials report how symptoms evolved in observed populations over a matter of weeks, generally ranging from two weeks up to three months.

Gaps and Limitations in the Existing Research

The research base has a stronger foundation for acute pain models than for chronic, fluctuating conditions. The available evidence for chronic pain usually involves follow-up durations that were limited, typically no longer than three months in highly controlled settings. Consequently, long-term effects are not fully established. Research describes what has been observed for shorter periods—and what remains uncertain regarding outcomes after extended use. Furthermore, the data for certain groups remain insufficient, meaning that comparative evidence is lacking, and results apply primarily to the specific populations studied.

Frequently Asked Questions (FAQ)

Common questions about Dolex-P (FAQ)

Q: What conditions are typically treated with Dolex-P?

According to official regulatory documents, Dolex-P is indicated for the symptomatic treatment of moderate to severe pain. Regulatory documents state that use is for situations where a healthcare professional has determined that the pain requires the combined action of both Tramadol and Paracetamol.

Q: How is Dolex-P generally described in official medical sources?

Dolex-P is generally described in official sources as a fixed-dose combination (FDC) product. It is classified as a Multimodal Analgesic because it contains two distinct agents: a non-opioid medicine (Paracetamol) and a synthetic opioid agent (Tramadol).

Q: How quickly can a person expect Dolex-P to start relieving symptoms?

Pharmacokinetic studies provide insight into absorption timing. The Paracetamol component typically reaches its highest concentration in the blood around 0.9 hours, while the Tramadol component reaches its peak around 1.8 hours. These times reflect when the active substances reach their highest concentration in the bloodstream.

Q: Does the body process Dolex-P differently depending on the user's age?

Yes. Official pharmacokinetic data indicates that the drug’s breakdown and elimination may differ by age. For instance, the elimination of the Tramadol component and its active metabolite is often prolonged in older patients. Conversely, Paracetamol's half-life is described as shorter in children compared to adults.

Q: Is Dolex-P used for both inflammatory and non-inflammatory pain conditions?

Studies and official information indicate that the combined mechanism of action is generally applicable to managing both inflammatory and non-inflammatory types of pain. The medication influences pain signaling through the COX pathway (relevant to inflammation) and by acting on central opioid receptors in the brain and spinal cord.

Q: Is it true that Dolex-P has a potential risk of interaction with blood thinning medications?

Yes. Regulatory information specifically states that co-administration with blood thinners, such as Warfarin, may potentiate their effects. This means the combination could increase the risk of major bleeding complications, and the combination may necessitate close monitoring of coagulation tests by a healthcare provider.

Q: What is the meaning of the 'P' in the drug name Dolex-P?

The 'P' in the brand name Dolex-P typically refers to one of its active ingredients, Paracetamol (also known as Acetaminophen). Official information describes Dolex-P as a fixed-dose combination product containing both Paracetamol and the opioid agent Tramadol.

Q: Is Dolex-P the same type of medication as ibuprofen?

No, Dolex-P is classified as a multimodal analgesic because it combines two different types of medicine: an opioid agent (Tramadol) and Paracetamol. In contrast, ibuprofen is a separate class of medication known as a non-steroidal anti-inflammatory drug (NSAID), meaning they have different primary mechanisms of action.

Q: Can I take over-the-counter cold or allergy medicine while using Dolex-P?

Official regulatory warnings advise extreme caution regarding combination use. It is contraindicated to use Dolex-P with any other product that already contains Paracetamol or Tramadol. Additionally, regulatory documents advise caution with other medications, such as some cold or allergy products, that cause CNS depression due to the risk of enhanced effects.

Q: What information is available in official sources about taking Dolex-P while breastfeeding?

Official safety information indicates that Tramadol, one of the active ingredients, passes into breast milk in very small amounts. While generally considered unlikely to cause side effects in the infant when used short-term, the decision to use the medicine should involve an assessment of risk.

Q: Does Dolex-P interact with common antidepressant or anxiety medications?

Yes. Official regulatory documents warn about interactions with two main categories of medicines that include antidepressants and anxiety treatments. Combining Dolex-P with serotonergic drugs (like many antidepressants) can increase the risk of Serotonin Syndrome. It may also enhance the effects of CNS depressants (like some anxiety medicines).

Q: Are there known interactions between Dolex-P and common herbal supplements like St. John's Wort?

Yes, official documentation explicitly mentions the herbal supplement St. John's Wort as a known interacting substance. It is described as a CYP3A4 inducer, which is a process that may increase the metabolism of the Tramadol component and lead to decreased exposure to the active medicine.

Q: What are the specific regulatory safety classifications assigned to Dolex-P (e.g., pregnancy category)?

Official documents describe a risk profile for the medicine due to the presence of the Tramadol component. Regulatory warnings state that prolonged use of Dolex-P during pregnancy can lead to the risk of Neonatal Opioid Withdrawal Syndrome in the newborn after delivery. Animal studies have also described the potential for embryotoxic and fetotoxic effects.

Q: Why is Dolex-P sometimes packaged with a special warning about liver function?

The special warning is included because of the Paracetamol component and the potential risk of hepatotoxicity (severe liver damage). This risk is particularly high in cases of overdose, when the liver's protective substances are overwhelmed by a toxic metabolite produced during the breakdown of Paracetamol.

Q: Are there any restrictions on using Dolex-P for people with pre-existing kidney issues?

Yes. The medication is contraindicated (should not be used) in patients with severe kidney disease. For individuals with other degrees of impaired kidney function, regulatory documents describe the need to restrict the maximum dose and prolong the dosing interval.

Q: Is Dolex-P suitable for use in older adults (e.g., people over 65)?

Official documents note that older patients, particularly those over the age of 75, may exhibit increased sensitivity to the effects of the medication. This can lead to a higher risk of adverse effects, and official guidance describes the need for careful consideration of their medical profile.

How should Dolex-P be stored and disposed of?

How to Store and Dispose of Dolex-P

Storage of Dolex-P (Paracetamol and Tramadol HCl tablets) must adhere strictly to labeled conditions to maintain product stability.

Storage Requirements

The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C. It is required to keep the medication in its original container with the lid tightly closed and to protect the tablets from moisture. The product must not be frozen.

Child Safety: All doses must be kept out of the reach and sight of children.

Disposal Instructions

Disposal must follow guidelines for controlled substances. Do not flush Dolex-P down the toilet or pour it down a sink. Unused or expired medication should be taken to a medicine take-back program or a community drug disposal location when available. If take-back is not possible, the product should be mixed with an unappealing substance, sealed in a plastic bag, and placed in the household trash.

Dolex-P